Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Israeli medical company seeks investment.
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Assistant Manager, International Business Advisory
|Project highlights||Ophthalmology medical - CE-certified III drug & clinical evidence - increase compliance|
The Israeli medical company has a product that is a microemulsion composed of phospholipids and triglycerides. It can form a tear film like elastic lipid shield to improve vision. It is a CE-certified III drug. Project is designated for post-operative ophthalmic surgery (e.g., refractive surgery, cataract surgery, and corneal transplantation), corneal erosion, and dry eye syndrome. This product is the only product on the eye drops market with clinical evidence that corneal epithelium thickens again after mechanical, traumatic, and surgical epithelial loss. As a microemulsion carrier, the technology can be used as a drug delivery platform in the pre-clinical stage. Its unique pharmaceutical advantages include a longer contact time between drug and eye surface which can increase compliance. The company seeks investment.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us